Cargando…

Defibrotide in the treatment of hepatic veno-occlusive disease

Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), represents the most frequent complication in patients in early phase following hematopoietic stem-cell transplantation (HSCT). In its severe form, VOD/SOS can be associated with multiorgan failure and with a m...

Descripción completa

Detalles Bibliográficos
Autores principales: Fulgenzi, Alessandro, Ferrero, Maria Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098529/
https://www.ncbi.nlm.nih.gov/pubmed/27843363
http://dx.doi.org/10.2147/HMER.S79243
_version_ 1782465797712510976
author Fulgenzi, Alessandro
Ferrero, Maria Elena
author_facet Fulgenzi, Alessandro
Ferrero, Maria Elena
author_sort Fulgenzi, Alessandro
collection PubMed
description Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), represents the most frequent complication in patients in early phase following hematopoietic stem-cell transplantation (HSCT). In its severe form, VOD/SOS can be associated with multiorgan failure and with a mortality rate >80% by day +100. Defibrotide (DF) (a mixture of 90% single-stranded phosphodiester oligonucleotides and 10% double-stranded phosphodiester oligonucleotides derived from controlled depolarization of porcine intestinal mucosal DNA) has been proposed for the treatment of SOS due to its ability to restore thrombo-fibrinolytic balance and protect endothelial cells. The present review highlights why the mechanisms of action of DF allow its successful use in the prevention and treatment of SOS following HSCT.
format Online
Article
Text
id pubmed-5098529
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50985292016-11-14 Defibrotide in the treatment of hepatic veno-occlusive disease Fulgenzi, Alessandro Ferrero, Maria Elena Hepat Med Review Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), represents the most frequent complication in patients in early phase following hematopoietic stem-cell transplantation (HSCT). In its severe form, VOD/SOS can be associated with multiorgan failure and with a mortality rate >80% by day +100. Defibrotide (DF) (a mixture of 90% single-stranded phosphodiester oligonucleotides and 10% double-stranded phosphodiester oligonucleotides derived from controlled depolarization of porcine intestinal mucosal DNA) has been proposed for the treatment of SOS due to its ability to restore thrombo-fibrinolytic balance and protect endothelial cells. The present review highlights why the mechanisms of action of DF allow its successful use in the prevention and treatment of SOS following HSCT. Dove Medical Press 2016-10-31 /pmc/articles/PMC5098529/ /pubmed/27843363 http://dx.doi.org/10.2147/HMER.S79243 Text en © 2016 Fulgenzi and Ferrero. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Fulgenzi, Alessandro
Ferrero, Maria Elena
Defibrotide in the treatment of hepatic veno-occlusive disease
title Defibrotide in the treatment of hepatic veno-occlusive disease
title_full Defibrotide in the treatment of hepatic veno-occlusive disease
title_fullStr Defibrotide in the treatment of hepatic veno-occlusive disease
title_full_unstemmed Defibrotide in the treatment of hepatic veno-occlusive disease
title_short Defibrotide in the treatment of hepatic veno-occlusive disease
title_sort defibrotide in the treatment of hepatic veno-occlusive disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098529/
https://www.ncbi.nlm.nih.gov/pubmed/27843363
http://dx.doi.org/10.2147/HMER.S79243
work_keys_str_mv AT fulgenzialessandro defibrotideinthetreatmentofhepaticvenoocclusivedisease
AT ferreromariaelena defibrotideinthetreatmentofhepaticvenoocclusivedisease